MGP
HZNP

Metis Global Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Metis Global Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,556
Closed -$643K – 764
2023
Q3 		$643K Buy
5,556
+610
+12% +$65.5K 0.03% 479
2023
Q2 		$509K Sell
4,946
-295
-6% -$31.1K 0.03% 519
2023
Q1 		$572K Buy
+5,241
New +$579K 0.04% 456

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Metis Global Partners's HZNP Position: Q4 2023 in Review

Metis Global Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 5,556 shares — an estimated $643K sold.

Metis Global Partners first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $643K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Metis Global Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Metis Global Partners sold 5,556 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $643K.
  • Metis Global Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Metis Global Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $643K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Metis Global Partners's 13F filing for Q4 2023, filed 6 Feb 2024.